EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Galmed Pharmaceuticals Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 31, 2026
$2.85−0.00 (-0.00%)
Close on Oct 19, 2026
- Market cap
- $2.71M
- P/E (TTM)
- 0.1
- Dividend yield
- –
Share price
−$8.11 (−74.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.71M
- P/E ratio
- 0.1
- Price to sales
- –
- Price to book
- 0.21
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.34M
- EPS, diluted
- $19.12
- Book value per share
- $13.38
- Diluted shares
- 1M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
–
Net income
-$11.34M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months